BiologicalDrug
Recombinant human INTERLEUKIN-15 clinical trials
Also written rhIL-15.
Keep track of what changes. Save the recombinant human INTERLEUKIN-15 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 9
National Cancer Institute (NCI) (8) · Masonic Cancer Center, University of Minnesota (1)
Often tested with
Tested in the same studies.
Mogamulizumab (1) · Avelumab (1) · Temozolomide (1) · Irinotecan (1) · Obinutuzumab (1)
Studies
Open first, then newest update. How each study uses recombinant human INTERLEUKIN-15 is read from its arms, and is right about nine times in ten.
Testing it · 9
- Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory NeuroblastomaRecruitingPhase 1National Cancer Institute (NCI)NCT06995872Written as rhIL-15
- NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT01875601Written as Recombinant human interleukin-15 (rhIL-15)
- Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)CompletedPhase 1Masonic Cancer Center, University of MinnesotaNCT01385423Written as Intravenous Recombinant Human IL-15 (rhIL-15)
- Continuous Infusion of rhIL-15 for Adults With Advanced CancerCompletedPhase 1National Cancer Institute (NCI)NCT01572493Written as rh IL-15 (10 DAYS)
- Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary SyndromeCompletedPhase 1National Cancer Institute (NCI)NCT04185220Written as Recombinant human Interleukin-15 (rhIL-15)
- Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell MalignanciesCompletedPhase 1National Cancer Institute (NCI)NCT03905135Written as rhIL-15
- Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte LeukemiaTerminatedPhase 1National Cancer Institute (NCI)NCT03759184Written as rhIL-15
- A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell CancerCompletedPhase 1National Cancer Institute (NCI)NCT01021059Written as rh IL-15
- Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck CancerCompletedPhase 1National Cancer Institute (NCI)NCT01727076Written as Recombinant Human Interleukin-15
Given in every arm · 2 — recombinant human INTERLEUKIN-15 is usual care beside what is tested
- Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory CancersCompletedPhase 1National Cancer Institute (NCI)NCT03388632Written as rhIL-15
- Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal CarcinomaTerminatedPhase 2National Cancer Institute (NCI)NCT04150562Written as rhIL-15
Codes
What other systems call recombinant human INTERLEUKIN-15 · ClinicalTrials.gg INT018258
- UNII (FDA) VL2UPV1APWRECOMBINANT HUMAN INTERLEUKIN-15One source FDA
- NCI Thesaurus C1545Recombinant Human Interleukin-15One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | VL2UPV1APW | RECOMBINANT HUMAN INTERLEUKIN-15 | One source FDA |
| NCI Thesaurus | C1545 | Recombinant Human Interleukin-15 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.